Single User License
INR 128560
Site License
INR 257120
Corporate User License
INR 385680

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Marburg Hemorrhagic Fever-Pipeline Review, H2 2015

Marburg Hemorrhagic Fever-Pipeline Review, H2 2015


  • Products Id :- GMDHC7024IDB
  • |
  • Pages: 48
  • |
  • August 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Marburg Hemorrhagic Fever-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Marburg Hemorrhagic Fever-Pipeline Review, H2 2015', provides an overview of the Marburg Hemorrhagic Fever's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Marburg Hemorrhagic Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Marburg Hemorrhagic Fever and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Marburg Hemorrhagic Fever

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Marburg Hemorrhagic Fever and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Marburg Hemorrhagic Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Marburg Hemorrhagic Fever pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Marburg Hemorrhagic Fever

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Marburg Hemorrhagic Fever pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Marburg Hemorrhagic Fever Overview 6

Therapeutics Development 7

Pipeline Products for Marburg Hemorrhagic Fever-Overview 7

Pipeline Products for Marburg Hemorrhagic Fever-Comparative Analysis 8

Marburg Hemorrhagic Fever-Therapeutics under Development by Companies 9

Marburg Hemorrhagic Fever-Pipeline Products Glance 10

Clinical Stage Products 10

Early Stage Products 11

Marburg Hemorrhagic Fever-Products under Development by Companies 12

Marburg Hemorrhagic Fever-Companies Involved in Therapeutics Development 13

Arbutus Biopharma Corporation 13

Crucell N.V. 14

GlaxoSmithKline Plc 15

Immunovaccine, Inc. 16

Integrated BioTherapeutics, Inc. 17

Sarepta Therapeutics, Inc. 18

Marburg Hemorrhagic Fever-Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Combination Products 20

Assessment by Target 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Drug Profiles 27

AVI-7288-Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

ebola [strain sudan, zaire] + marburg vaccine-Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

marburg vaccine-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

marburg vaccine-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Monoclonal Antibodies for Ebola and Marburg Infections-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Monoclonal Antibody for Marburg Virus-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

panfilovirus (multivalent) vaccine-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

TKM-Marburg-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Marburg Hemorrhagic Fever-Recent Pipeline Updates 37

Marburg Hemorrhagic Fever-Dormant Projects 40

Marburg Hemorrhagic Fever-Product Development Milestones 41

Featured News & Press Releases 41

Jul 22, 2015: Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplus platform 41

Feb 10, 2014: Sarepta Therapeutics Announces Positive Safety Results from Phase I Clinical Study of Marburg Drug Candidate 42

Nov 12, 2013: Tekmira Announces New Preclinical Data On TKM-Marburg 42

Oct 08, 2013: Tekmira Provides Corporate Update On RNAi Therapeutics Product TKM-Marburg 43

Sep 25, 2013: Tekmira Presents New Anti-Viral Efficacy Data Against the Marburg Hemorrhagic Fever Virus 44

May 07, 2013: Sarepta Therapeutics Initiates Dosing In Phase I Multiple Ascending Dose Study Of Drug For Treatment Of Marburg Virus 45

Mar 04, 2013: Sarepta Therapeutics's Marburg Drug Shows High Survival Rates After Intramuscular Delivery In Non-Human Primates 46

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

Number of Products under Development for Marburg Hemorrhagic Fever, H2 2015 7

Number of Products under Development for Marburg Hemorrhagic Fever-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Comparative Analysis by Clinical Stage Development, H2 2015 10

Comparative Analysis by Early Stage Development, H2 2015 11

Products under Development by Companies, H2 2015 12

Marburg Hemorrhagic Fever-Pipeline by Arbutus Biopharma Corporation, H2 2015 13

Marburg Hemorrhagic Fever-Pipeline by Crucell N.V., H2 2015 14

Marburg Hemorrhagic Fever-Pipeline by GlaxoSmithKline Plc, H2 2015 15

Marburg Hemorrhagic Fever-Pipeline by Immunovaccine, Inc., H2 2015 16

Marburg Hemorrhagic Fever-Pipeline by Integrated BioTherapeutics, Inc., H2 2015 17

Marburg Hemorrhagic Fever-Pipeline by Sarepta Therapeutics, Inc., H2 2015 18

Assessment by Monotherapy Products, H2 2015 19

Assessment by Combination Products, H2 2015 20

Number of Products by Stage and Target, H2 2015 22

Number of Products by Stage and Route of Administration, H2 2015 24

Number of Products by Stage and Molecule Type, H2 2015 26

Marburg Hemorrhagic Fever Therapeutics-Recent Pipeline Updates, H2 2015 37

Marburg Hemorrhagic Fever-Dormant Projects, H2 2015 40

List of Figures

Number of Products under Development for Marburg Hemorrhagic Fever, H2 2015 7

Number of Products under Development for Marburg Hemorrhagic Fever-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Comparative Analysis by Clinical Stage Development, H2 2015 10

Comparative Analysis by Early Stage Products, H2 2015 11

Assessment by Monotherapy Products, H2 2015 19

Number of Products by Top 10 Targets, H2 2015 21

Number of Products by Stage and Top 10 Targets, H2 2015 21

Number of Products by Top 10 Routes of Administration, H2 2015 23

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 23

Number of Products by Top 10 Molecule Types, H2 2015 25

Number of Products by Stage and Top 10 Molecule Types, H2 2015 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Arbutus Biopharma Corporation

Crucell N.V.

GlaxoSmithKline Plc

Immunovaccine, Inc.

Integrated BioTherapeutics, Inc.

Sarepta Therapeutics, Inc.

Marburg Hemorrhagic Fever Therapeutic Products under Development, Key Players in Marburg Hemorrhagic Fever Therapeutics, Marburg Hemorrhagic Fever Pipeline Overview, Marburg Hemorrhagic Fever Pipeline, Marburg Hemorrhagic Fever Pipeline Assessment


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com